Dilated cardiomyopathy: reconceptualization of the problem
https://doi.org/10.15829/1560-4071-2019-4-35-47
Abstract
Dilated cardiomyopathy (DCM) is a complex, etiologically heterogeneous myocardial disease, which is one of the main causes of heart failure and heart transplantation. In 2016, experts from the European working group proposed a new definition of cardiomyopathy, which includes intermediate variants with a change in phenotype in carriers of mutations from subclinical form to the full manifestations of the disease. The classification of DCM was supplemented with intermediate phenotypes with the inclusion of a hypokinetic form with reduced contractile function without ventricular dilatation and variants with predominant dilation or arrhythmogenicity. Pathological architectonics of DCM consists of many genetic determinants that interact with numerous environmental factors. Clinical manifestations depend not only on the malignancy and penetrance of the gene mutation, but also on a number of other causes — epigenomic factors, age, toxic effects, environmental aggressiveness, pregnancy, and the effects of other acquired diseases. The article summarizes the current epidemiological data and ideas about specific molecular changes with an unfavorable prognosis. For clarity, we present clinical observations of familial DCM with mutations in the RBM20 and LMNA genes.
About the Authors
T. G. Vaykhanskaya
Scientific and Practical Center “Cardiology”
Belarus
Minsk
Competing Interests: нет конфликта интересов
Belarus
Minsk
Competing Interests: нет конфликта интересов
L. N. Sivitskaya
Institute of Genetics and Cytology
Belarus
Minsk
Competing Interests: нет конфликта интересов
Belarus
Minsk
Competing Interests: нет конфликта интересов
T. V. Kurushko
Scientific and Practical Center “Cardiology”
Belarus
Minsk
Competing Interests: нет конфликта интересов
Belarus
Minsk
Competing Interests: нет конфликта интересов
O. D. Levdansky
Institute of Genetics and Cytology
Belarus
Minsk
Competing Interests: нет конфликта интересов
Belarus
Minsk
Competing Interests: нет конфликта интересов
N. G. Danilenko
Institute of Genetics and Cytology
Belarus
Minsk
Competing Interests:
Belarus
Minsk
Competing Interests:
нет конфликта интересов
References
1. Литература
2. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270–276. doi: 10.1093/eurheartj/ehm342.
3. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10:531–547. doi:10.1038/nrcardio.2013.105.
4. Williams DG, Olsen EG. Prevalence of overt dilated cardiomyopathy in two regions of England. Heart. 1985;54:153–155. doi: 10.1136/hrt.54.2.153
5. Codd MB, Sugrue DD, Gersh BJ, Melton LJ. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation. 1989;80:564–572. doi: 10.1161/01.CIR.80.3.564.
6. Petretta M, Pirozzi F, Sasso L, et al. Review and meta-analysis of the frequency of familial dilated cardiomyopathy. The American Journal of Cardiology 2011;108:1171–1176. doi: 10.1016/j.amjcard.2011.06.022.
7. Sweet M, Taylor MR, Mestroni L. Diagnosis, prevalence, and screening of familial dilated cardiomyopathy. Expert Opin Orphan Drugs. 2015;3:869–876. doi: 10.1517/21678707.2015.1057498.
8. Charron P, Elliott PM, Gimeno JR, et al. The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. Eur Heart J. 2018;29:270–310. doi: 10.1093/eurheartj/ehx819.
9. Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 2016;37:1850–1858. doi: 10.1093/eurheartj/ehv727.
10. McNally EM, Mestroni L. Dilated Cardiomyopathy: Genetic Determinants and Mechanisms. Circ Res American Heart Association 2017;121:731–748. doi: 10.1161/CIRCRESAHA.116.309396
11. Hasselberg NE, Edvardsen T, Petri H, et al. Risk prediction of ventricular arrhythmias and myocardial function in Lamin A/C mutation positive subjects. Europace 2014;16:563–571. doi: 10.1093/europace/eut291.
12. Bozkurt B, Colvin M, Cook J, et al. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association.Circulation. 2016;134(23):e579-e646. doi: 10.1161/CIR.0000000000000455.
13. Narula N, Favalli V, Tarantino P, et al. Quantitative expression of the mutated lamin A/C gene in patients with cardiolaminopathy. J Am Coll Cardiol 2012;60:1916–1920. doi: 10.1016/j.jacc.2012.05.059.
14. Anastasakis A, Papatheodorou E, Ritsatos K, et al. Sudden unexplained death in the young:epidemiology, aetiology and value of the clinically guided genetic screening. Europace 2018;20(3):472-480. doi: 10.1093/europace/euw362.
15. Favalli V, Serio A, Grasso M, Arbustini E. Genetic causes of dilated cardiomyopathy. Heart. 2016;102(24):2004-2014. doi: 10.1136/heartjnl-2015-308190.
16. Garcia J, Tahiliani J, Johnson NM, et al. Clinical genetic testing for the cardiomyopathies and arrhythmias: a systematic framework for establishing clinical validity and addressing genotypic and phenotypic heterogeneity. Front Cardiovasc Med. 2016;3:20. doi: 10.3389/fcvm.2016.00020.
17. Harakalova M, Kummeling G, Sammani A, et al. A systematic analysis of genetic dilated cardiomyopathy reveals numerous ubiquitously expressed and muscle-specific genes. Eur J Heart Fail. 2015;17:484–493. doi: 10.1002/ejhf.255.
18. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424. doi: 10.1038/gim.2015.30.
19. Lahrouchi N, Raju H, Lodder EM, et al. Utility of Post-Mortem Genetic Testing in Cases of Sudden Arrhythmic Death Syndrome. J Am Coll Cardiol. 2017;69(17):2134-2145. doi: 10.1016/j.jacc.2017.02.046.
20. Gigli M, Begay RL, Morea G, et al. A review of the giant protein titin in clinical molecular diagnostics of cardiomyopathies. Front Cardiovasc Med. 2016;3:21. doi: 10.3389/fcvm.2016.00021.
21. Akinrinade O, Ollila L, Vattulainen S, et al. Genetics and genotype-phenotype correlations in Finnish patients with dilated cardiomyopathy. Eur Heart J. 2015;36:2327–2337. doi: 10.1093/eurheartj/ehv253.
22. Begay RL, Graw S, Sinagra G, et al. Role of titin missense variants in dilated cardiomyopathy. J Am Heart Assoc. 2015; 4(11): e002645. doi: 10.1161/JAHA.115.002645.
23. Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366(7):619-628. doi: 10.1056/NEJMoa1110186.
24. Norton N, Li D, Rampersaud E, et al. Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy. Circ Cardiovasc Genet. 2013;6(2):144-53. doi: 10.1161/CIRCGENETICS.
25. Haas J, Frese KS, Peil B, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J 2015;36:1123–1135. doi: 10.1093/eurheartj/ehu301.
26. Walsh R, Thomson KL, Ware JS, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med. 2017;19:192–203. doi: 10.1038/gim.2016.90.
27. Verdonschot JAJ, Hazebroek MR, Derks KWJ, et al. Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. Eur Heart J. 2018; 39(10):864-873. doi: 10.1093/eurheartj/ehx808.
28. Tayal U, Newsome S, Buchan R, et al. Phenotype and Clinical Outcomes of Titin Cardiomyopathy. Journal of the American College of Cardiology. 2017;70:2264–2274. doi: 10.1016/j.jacc.2017.08.063
29. Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366(7):619–628. doi: 10.1056/NEJMoa1110186.
30. Tayal U, Prasad SK. Titin cardiomyopathy: why we need to go big to understand the giant. Eur Heart J. 2018;39:874–875. doi: 10.1093/eurheartj/ehy109.
31. Akinrinade O, Alastalo TP, Koskenvuo JW. Relevance of truncating titin mutations in dilated cardiomyopathy. Clin Genet. 2016;90(1):49–54. doi:10.1111/cge.1274
32. Guo W, Schafer S, Greaser ML, et al. RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. Nat Med; 2012;18(5):766–773. doi: 10.1038/nm.2693.
33. van den Hoogenhof MMG, Beqqali A, Amin AS, et al. RBM20 mutations induce an arrhythmogenic dilated cardiomyopathy related to disturbed calcium handling. Circulation; 2018; 138:1330-1342. doi.org/10.1161/CIRCULATIONAHA.117.031947
34. Kayvanpour E, Sedaghat-Hamedani F, Amr A, et al. Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals. Clin Res Cardiol 2017;106(2):127–139.doi:10.1007/s00392-016-1033-6
35. Parks SB, Kushner JD, Nauman D, et al. Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. Am Heart J. 2008;156(1):161-169. doi: 10.1016/j.ahj.2008.01.026.
36. Ortiz-Genga MF, Cuenca S, Dal Ferro M, et al. Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. Journal of the American College of Cardiology. 2016;68:2440–2451. doi: 10.1016/j.jacc.2016.09.927.
37. Arbustini E, Pasotti M, Pilotto A, et al. Desmin accumulation restrictive cardiomyopathy and atrioventricular block associated with desmin gene defects. Eur J Heart Fail. 2006;8:477–483. doi: 10.1016/j.ejheart.2005.11.003
38. Capetanaki Y, Papathanasiou S, Diokmetzidou A, et al. Desmin related disease: a matter of cell survival failure. Current Opinion in Cell Biology. 2015;32:113–120. doi: 10.1016/j.ceb.2015.01.004.
39. Young HS, Ceholski DK, Trieber CA. Deception in simplicity: Hereditary phospholamban mutations in dilated cardiomyopathy. Biochemistry and Cell Biology, 2015; 93(1): 1-7. doi: 10.1139/bcb-2014-0080
40. van der Zwaag PA, van Rijsingen IAW, Asimaki A, et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail, 2012;14(11):1199–1207. doi: 10.1093/eurjhf/hfs119.
41. McNair WP, Sinagra G, Taylor MRG, et al. Familial Cardiomyopathy Registry Research Group. SCN5A Mutations Associate With Arrhythmic Dilated Cardiomyopathy and Commonly Localize to the Voltage-Sensing Mechanism. Journal of the American College of Cardiology 2011;57:2160–2168. doi: 10.1016/j.jacc.2010.09.084.
42. Zaklyazminskaya E, Dzemeshkevich S. The role of mutations in the SCN5A gene in cardiomyopathies. Biochim Biophys Acta. 2016;1863:1799–1805. doi: 10.1016/j.bbamcr.2016.02.014.
43. Tayal U. Genetics and genomics of dilated cardiomyopathy and systolic heart failure. Genome Med 2017;9:20. doi: 10.1186/s13073-017-0410-8.
44. van Rijsingen IAW, Arbustini E, Elliott PM, et al. Risk Factors for Malignant Ventricular Arrhythmias in Lamin A/C Mutation Carriers. Journal of the American College of Cardiology. 2012;59:493–500. doi: 10.1016/j.jacc.2011.08.078.
45. Elliott P, O'Mahony C, Syrris P, et al. Prevalence of Desmosomal Protein Gene Mutations in Patients With Dilated Cardiomyopathy. Circ Cardiovasc Genet 2010;3:314–322. doi: 10.1161/CIRCGENETICS.110.937805.
46. Spezzacatene A, Sinagra G, Merlo M, et al. The familial Cardiomyopathy Registry. Arrhythmogenic Phenotype in Dilated Cardiomyopathy: Natural History and Predictors of Life‐Threatening Arrhythmias. J Am Heart Assoc 2015;4:e002149–10. doi: 10.1161/JAHA.115.002149.
47. Stillitano F, Turnbull IC, Karakikes I, et al. Genomic correction of familial cardiomyopathy in human engineered cardiac tissues. Eur Heart J 2016;37:3282–3284. doi: 10.1093/eurheartj/ehw307
48. Mogensen J, van Tintelen JP, Fokstuen S, et al. The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. Eur Heart J 2015;36:1367–1370. doi: 10.1093/eurheartj/ehv122.
49. Rapezzi C, Arbustini E, Caforio AL, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(19):1448-58. doi: 10.1093/eurheartj/ehs397.
50. Japp AG, Gulati A, Cook SA, et al. The Diagnosis and Evaluation of Dilated Cardiomyopathy. J Am Coll Cardiol. 2016;67(25):2996-3010. doi: 10.1016/j.jacc.2016.03.590.
51. Bollen IAE, Schuldt M, Harakalova M, et al. Genotype-specific pathogenic effects in human dilated cardiomyopathy. J Physiol (Lond) 2017;595(14):4677–4693. doi: 10.1113/JP274145.
52. Merlo M, Cannatà A, Gobbo M, et al. Evolving concepts in dilated cardiomyopathy. Eur J Heart Fail 2018;20(2):228–239. doi: 10.1002/ejhf.1103.
53. Di marco A, Anguera I, Schmitt M, et al. Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Review and Meta-Analysis. JACC Heart Fail. 2017;5(1):28-38. doi: 10.1016/j.jchf.2016.09.017.
54. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Eur Heart J. 2015;36:2793–2867. doi: 10.1093/eurheartj/ehv316.
55. Botto N, Vittorini S, Colombo MG, et al. A novel LMNA mutation (R189W) in familial dilated cardiomyopathy: evidence for a ‘hot spot’ region at exon 3: a case report. Cardiovascular Ultrasound. 2010; 8:9–14. doi: 10.1186/1476-7120-8-9.
56. Hasselberg NE, Haland TF, Saberniak J, et al. Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation. Eur Heart J. 2018;39(10):853–860. doi: 10.1093/eurheartj/ehx596.
57. Pankuweit S. Lamin A/C mutations in patients with dilated cardiomyopathy. Eur Heart J. 2018;39:861–863. doi:10.1093/eurheartj/ehx650.
58. Loebel M, Holzhauser L, Hartwig JA, et al. The forkhead transcription factor Foxo3 negatively regulates natural killer cell function and viral clearance in myocarditis. Eur Heart J. 2018;39:876–887. doi: 10.1093/eurheartj/ehx624.
59. van Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, et al. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. Eur Heart J. 2014;35:2165–2173. doi: 10.1093/eurheartj/ehu050.
Review
For citations:
Vaykhanskaya T.G., Sivitskaya L.N., Kurushko T.V., Levdansky O.D., Danilenko N.G. Dilated cardiomyopathy: reconceptualization of the problem. Russian Journal of Cardiology. 2019;(4):35-47. (In Russ.) https://doi.org/10.15829/1560-4071-2019-4-35-47
Views:
11572
Email this article 